PharmiWeb.com - Global Pharma News & Resources
14-Jun-2023

Vetter Again Demonstrates Industry Leadership in Sustainability Initiatives

Globally-operating CDMO publishes annual sustainability report

  • Report now includes Scope 3 emissions
  • Employee-driven social responsibility takes precedence as driving force for sustainability activities
  • Goal to reduce total emissions globally by ten percent by 2029

RAVENSBURG, Germany, June 14, 2023 / B3C newswire / -- Vetter, one of the world's leading Contract Development and Manufacturing Organizations (CDMO), is consistently pursuing improvements to its sustainability strategy. The globally-operating company released its second-annual sustainability report. For the first time, the pharmaceutical service provider headquartered in Ravensburg, Germany, also reports its Scope 3 emissions and shows its CO2 balance according to the requirements of the international Greenhouse Gas Protocol. Adding to its dynamic growth, the company was able to significantly reduce electricity consumption and CO2 emissions per euro of gross value added compared to the previous year. By 2029, the total emissions in relation to gross value added are to be reduced by ten percent compared to the base year 2019.

Sustainability creates resilience and reliability in the supply chain
"We support our customers in the production of high-quality and vital medicines for their patients worldwide,” says Managing Director Thomas Otto. “Hardly any other topic concerns our company as holistically as sustainability. Functioning supply chains are a non-negotiable for us. With our sustainability report, we make our measures, successes and goals even more transparent. This gives our partners confidence in implementing their own sustainability goals."

With 100 percent green electricity, the CDMO has been a sustainability pioneer in the pharmaceutical industry since 2014. Since then, Vetter has massively advanced the expansion and conversion of the individual company sites in the areas of renewable energies, resource efficiency and circular economy.

"Without the support from all levels of the company, and without the dedicated commitment of the management and the owner families, we would be nowhere near where we are today in terms of sustainability," added Henryk Badack, Senior Vice President Technical Services and Internal Project Management.

Focus on social responsibility
Assuming responsibility for employees and making a sustainable contribution to society is an important pillar of Vetter’s sustainability strategy. A comprehensive health management with target-group-oriented offers for employees in different life situations is as much a part of Vetter’s sustainability commitment as is the promotion of high-value training and development opportunities. For example, Vetter offers all employees a free supplementary company health insurance to fund additional services that are often not covered by statutory health insurance.

Furthermore, the CDMO secured first place in the 2022 Sustainable Impact Award in the category of Social Impact on Employees, which is awarded to the most attractive medium-sized employers with a focus on employee satisfaction.

Enhanced brand identity
Simultaneously, the pharmaceutical service provider is presenting its enhanced brand identity. According to Managing Director Peter Soelkner, “Our company is characterized by sustained, strong growth. Our mission is to improve the quality of life of patients worldwide and our aspiration is reliability – for our customers, suppliers and employees. In short: at all levels. With our newly launched enhanced brand, we want to make this promise even clearer – through strong corporate values and embedded in a dynamic design. Our new image authentically conveys what Vetter is all about and what we stand for."

Please find the Vetter Sustainabilty Report for download here.


                                
Vetter Sustainability Facts and Figures 2022
© Vetter Pharma International GmbH

Photovoltaic systems are a central element of Vetter’s sustainable energy concept
© Vetter Pharma International GmbH

For high resolution please click the images.

Find the Vetter press kit and more background information here.

 

About Vetter
Vetter is a leading Contract Development and Manufacturing Organization (CDMO) with headquarters in Ravensburg, Germany, and production facilities in Germany, Austria, and the U.S. As a global player, the pharmaceutical service provider is also present with its own sales locations in the Asia-Pacific markets of Japan, China, South Korea and Singapore. Around the world, small and large renowned pharma and biotech companies rely on the decades of experience, high quality, modern technologies, reliability, and commitment of more than 6,000 employees. The CDMO provides support from process development through clinical and commercial filling to a wide range of assembly and packaging services for vials, syringes, and cartridges. Thus Vetter contributes to improve the quality of life for patients worldwide. With innovative solutions, Vetter develops prefilled drug-delivery systems together with its customers to continuously improve patient safety, comfort, and compliance. The company is a pioneer in the industry when it comes to sustainability, and acts as a socially and ethically responsible corporate citizen. The CDMO is a member of the UN Global Compact, has received multiple CDMO Leadership Awards and was awarded several times as Best Managed Company. Founded in Ravensburg in 1950, the company remains family-owned to this day.


Contact

Vetter Pharma International GmbH
Markus Kirchner
Corporate Spokesperson / Media Relations
Eywiesenstrasse 5
88212 Ravensburg
Germany
+49 (0)751-3700-3729
PRnews@vetter-pharma.com

Keywords: Manufacturing and Industrial Facilities; Climate Change; Greenhouse Gases; Carbon Dioxide; Renewable Energy; Electricity; Geothermal Energy; Sunlight; Technology; Power Plants; Geothermal Energy; Social Participation; Sustainable Development; Social Responsibility; Conservation of Natural Resources; Pharmaceutical Services; Drug Packaging; Product Packaging; Drug Delivery Systems; Syringes; Outsourced Services; Commerce; Industry; Biotechnology; Germany

Published by B3C newswire

Editor Details

Last Updated: 14-Jun-2023